سوق البهاق العالمي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL VITILIGO MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL VITILIGO MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL VITILIGO MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMSUM INSIGHTS

4.1 PORTER'S 5 FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

5.1 INCIDENCE OF ALL BY GENDER

5.1.1 PREVALENCE OF VITILIGO

5.1.1.1. PREVALENCE E OF NONSEGMENTED VITILIGO

5.1.1.2. PREVALENCE OF SEGMENTED VITILIGO

5.1.1.3. PREVALENCE OF MIXED VITILIGO

5.1.2 INCEDENCE OF VITILIGO TREATED BY SURGERY

5.1.2.1. INCEDENCE OF VITILIGO TREATED BY SKIN GRAFT

5.1.2.2. INCEDENCE OF VITILIGO TREATED BY CELL TRANSPLANT

5.1.2.3. INCEDENCE OF VITILIGO TREATED BY MICROPIGMENTATION

5.2 TREATMENT RATE

5.3 MORTALITY RATE

5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

5.5 PATEINT TREATMENT SUCCESS RATES

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

6.7 INTERVIEWS WITH PATHOLOGIST

6.8 OTHER KOL SNAPSHOTS

7 REGULATORY SCENARIO

7.1 FDA APPROVALS

7.2 EMA APPROVALS

8 MERGERS AND ACQUISITION

8.1 LICENSING

8.2 COMMERCIALIZATION AGREEMENTS

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.4.1 RECELL DEVICE

9.4.2 SPRAY ON SKINTM CELLS

9.4.3 NB-UVB PHOTOTHERAPY

9.4.4 RAPAMYCIN

9.4.5 UPADACITINIB

9.4.6 INCB054707

9.4.7 AS012

9.4.8 AMG-714

9.4.9 TOFACITINIB

9.4.10 JAK1 INHIBITORS

9.4.10.1. PF-06651600

9.4.10.2. ARQ-252

9.4.10.3. CERDULATINIB

9.4.10.4. OTHERS

9.5 PHASE I CANDIDATE

9.5.1 VLRX001

9.5.2 BNZ-1

9.5.3 BOS-475

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

10 MARKET OVERVIEW

10.1 DRIVERS

10.2 RESTRAINS

10.3 OPPURTUNITY

10.4 CHALLENGES

11 GLOBAL VITILIGO MARKET, BY TYPE

11.1 OVERVIEW

11.2 NON SEGMENTAL VITILIGO

11.2.1 MEDICATION

11.2.1.1. TOPICAL CORTICOSTEROIDS

11.2.1.1.1. BY DRUGS

11.2.1.1.1.1 FLUTICASONE PROPIONATE

11.2.1.1.1.1.1. MARKET VALUE (USD MN)

11.2.1.1.1.1.2. MARKET VOLUME (SU)

11.2.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.2 BETAMETHASONE VALERATE

11.2.1.1.1.2.1. MARKET VALUE (USD MN)

11.2.1.1.1.2.2. MARKET VOLUME (SU)

11.2.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.3 HYDROCORTISONE BUTYRATE

11.2.1.1.1.3.1. MARKET VALUE (USD MN)

11.2.1.1.1.3.2. MARKET VOLUME (SU)

11.2.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.1.1.4 OTHERS

11.2.1.1.2. BY DRUG TYPE

11.2.1.1.2.1 GENERICS

11.2.1.1.2.2 BRANDED

11.2.1.1.2.2.1. ARUNITY ELLIPTA

1.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

2.2.1.1.1.1.1.1 MARKET VOLUME (SU)

3.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2.2. FLOVENT

4.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

5.2.1.1.1.1.1.1 MARKET VOLUME (SU)

6.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2.3. CELESTONE

7.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

8.2.1.1.1.1.1.1 MARKET VOLUME (SU)

9.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2.4. HYDROCORT

10.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

11.2.1.1.1.1.1.1 MARKET VOLUME (SU)

12.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2.5. ALPHOSYL

13.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

14.2.1.1.1.1.1.1 MARKET VOLUME (SU)

15.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.1.2.2.6. OTHERS

11.2.1.2. CALCINEURIN INHIBITORS

11.2.1.2.1. BY DRUGS

11.2.1.2.1.1 TACROLIMUS

11.2.1.2.1.1.1. MARKET VALUE (USD MN)

11.2.1.2.1.1.2. MARKET VOLUME (SU)

11.2.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.1.2 PIMECROLIMUS

11.2.1.2.1.2.1. MARKET VALUE (USD MN)

11.2.1.2.1.2.2. MARKET VOLUME (SU)

11.2.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.2.1.2.1.3 OTHERS

11.2.1.2.2. BY DRUG TYPE

11.2.1.2.2.1 GENERICS

11.2.1.2.2.2 BRANDED

11.2.1.2.2.2.1. ASTAGRAF XL

16.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

17.2.1.1.1.1.1.1 MARKET VOLUME (SU)

18.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.2.2.2.2. ENVARSUSXR

19.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

20.2.1.1.1.1.1.1 MARKET VOLUME (SU)

21.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.2.2.2.3. PROGRAF

22.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

23.2.1.1.1.1.1.1 MARKET VOLUME (SU)

24.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.2.2.2.4. ELIDED

25.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

26.2.1.1.1.1.1.1 MARKET VOLUME (SU)

27.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.2.1.2.2.2.5. OTHERS

11.2.1.3. CALCIPOTRIENE (DOVONEX)

11.2.1.3.1. MARKET VALUE (USD MN)

11.2.1.3.2. MARKET VOLUME (SU)

11.2.1.3.3. AVERAGE SELLING PRICE (USD)

11.2.1.4. RUXOLITINIB (OPZELURA)

11.2.1.4.1. MARKET VALUE (USD MN)

11.2.1.4.2. MARKET VOLUME (SU)

11.2.1.4.3. AVERAGE SELLING PRICE (USD)

11.2.1.5. VITAMIN D

11.2.1.5.1. MARKET VALUE (USD MN)

11.2.1.5.2. MARKET VOLUME (SU)

11.2.1.5.3. AVERAGE SELLING PRICE (USD)

11.2.1.6. OTHERS

11.2.2 THERAPY

11.2.2.1. LIGHT THERAPY

11.2.2.2. REPIGMENTATION THERAPY

11.2.2.3. CAMOUFLAGE THERAPY

11.2.3 SURGERY

11.2.3.1. SKIN GRAFT

11.2.3.2. CELL TRANSPLANT

11.2.3.3. MICROPIGMENTATION

11.2.3.4. OTHERS

11.3 SEGMENTAL VITILIGO

11.3.1 MEDICATION

11.3.1.1. TOPICAL CORTICOSTEROIDS

11.3.1.1.1. BY DRUGS

11.3.1.1.1.1 FLUTICASONE PROPIONATE

11.3.1.1.1.1.1. MARKET VALUE (USD MN)

11.3.1.1.1.1.2. MARKET VOLUME (SU)

11.3.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.2 BETAMETHASONE VALERATE

11.3.1.1.1.2.1. MARKET VALUE (USD MN)

11.3.1.1.1.2.2. MARKET VOLUME (SU)

11.3.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.3 HYDROCORTISONE BUTYRATE

11.3.1.1.1.3.1. MARKET VALUE (USD MN)

11.3.1.1.1.3.2. MARKET VOLUME (SU)

11.3.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.1.1.4 OTHERS

11.3.1.1.2. BY DRUG TYPE

11.3.1.1.2.1 GENERICS

11.3.1.1.2.2 BRANDED

11.3.1.1.2.2.1. ARUNITY ELLIPTA

28.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

29.2.1.1.1.1.1.1 MARKET VOLUME (SU)

30.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2.2. FLOVENT

31.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

32.2.1.1.1.1.1.1 MARKET VOLUME (SU)

33.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2.3. CELESTONE

34.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

35.2.1.1.1.1.1.1 MARKET VOLUME (SU)

36.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2.4. HYDROCORT

37.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

38.2.1.1.1.1.1.1 MARKET VOLUME (SU)

39.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2.5. ALPHOSYL

40.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

41.2.1.1.1.1.1.1 MARKET VOLUME (SU)

42.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.1.2.2.6. OTHERS

11.3.1.2. CALCINEURIN INHIBITORS

11.3.1.2.1. BY DRUGS

11.3.1.2.1.1 TACROLIMUS

11.3.1.2.1.1.1. MARKET VALUE (USD MN)

11.3.1.2.1.1.2. MARKET VOLUME (SU)

11.3.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.3.1.2.1.2 PIMECROLIMUS

11.3.1.2.1.2.1. MARKET VALUE (USD MN)

11.3.1.2.1.2.2. MARKET VOLUME (SU)

11.3.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.3.1.2.1.3 OTHERS

11.3.1.2.2. BY DRUG TYPE

11.3.1.2.2.1 GENERICS

11.3.1.2.2.2 BRANDED

11.3.1.2.2.2.1. ASTAGRAF XL

43.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

44.2.1.1.1.1.1.1 MARKET VOLUME (SU)

45.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.2.2.2.2. ENVARSUSXR

46.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

47.2.1.1.1.1.1.1 MARKET VOLUME (SU)

48.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.2.2.2.3. PROGRAF

49.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

50.2.1.1.1.1.1.1 MARKET VOLUME (SU)

51.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.2.2.2.4. ELIDED

52.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

53.2.1.1.1.1.1.1 MARKET VOLUME (SU)

54.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.3.1.2.2.2.5. OTHERS

11.3.1.3. CALCIPOTRIENE (DOVONEX)

11.3.1.3.1. MARKET VALUE (USD MN)

11.3.1.3.2. MARKET VOLUME (SU)

11.3.1.3.3. AVERAGE SELLING PRICE (USD)

11.3.1.4. RUXOLITINIB (OPZELURA)

11.3.1.4.1. MARKET VALUE (USD MN)

11.3.1.4.2. MARKET VOLUME (SU)

11.3.1.4.3. AVERAGE SELLING PRICE (USD)

11.3.1.5. VITAMIN D

11.3.1.5.1. MARKET VALUE (USD MN)

11.3.1.5.2. MARKET VOLUME (SU)

11.3.1.5.3. AVERAGE SELLING PRICE (USD)

11.3.1.6. OTHERS

11.3.2 THERAPY

11.3.2.1. LIGHT THERAPY

11.3.2.2. REPIGMENTATION THERAPY

11.3.2.3. CAMOUFLAGE THERAPY

11.3.3 SURGERY

11.3.3.1. SKIN GRAFT

11.3.3.2. CELL TRANSPLANT

11.3.3.3. MICROPIGMENTATION

11.3.3.4. OTHERS

11.4 MIXED VITILIGO

11.4.1 MEDICATION

11.4.1.1. TOPICAL CORTICOSTEROIDS

11.4.1.1.1. BY DRUGS

11.4.1.1.1.1 FLUTICASONE PROPIONATE

11.4.1.1.1.1.1. MARKET VALUE (USD MN)

11.4.1.1.1.1.2. MARKET VOLUME (SU)

11.4.1.1.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.2 BETAMETHASONE VALERATE

11.4.1.1.1.2.1. MARKET VALUE (USD MN)

11.4.1.1.1.2.2. MARKET VOLUME (SU)

11.4.1.1.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.3 HYDROCORTISONE BUTYRATE

11.4.1.1.1.3.1. MARKET VALUE (USD MN)

11.4.1.1.1.3.2. MARKET VOLUME (SU)

11.4.1.1.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.1.1.4 OTHERS

11.4.1.1.2. BY DRUG TYPE

11.4.1.1.2.1 GENERICS

11.4.1.1.2.2 BRANDED

11.4.1.1.2.2.1. ARUNITY ELLIPTA

55.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

56.2.1.1.1.1.1.1 MARKET VOLUME (SU)

57.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2.2. FLOVENT

58.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

59.2.1.1.1.1.1.1 MARKET VOLUME (SU)

60.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2.3. CELESTONE

61.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

62.2.1.1.1.1.1.1 MARKET VOLUME (SU)

63.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2.4. HYDROCORT

64.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

65.2.1.1.1.1.1.1 MARKET VOLUME (SU)

66.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2.5. ALPHOSYL

67.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

68.2.1.1.1.1.1.1 MARKET VOLUME (SU)

69.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.1.2.2.6. OTHERS

11.4.1.2. CALCINEURIN INHIBITORS

11.4.1.2.1. BY DRUGS

11.4.1.2.1.1 TACROLIMUS

11.4.1.2.1.1.1. MARKET VALUE (USD MN)

11.4.1.2.1.1.2. MARKET VOLUME (SU)

11.4.1.2.1.1.3. AVERAGE SELLING PRICE (USD)

11.4.1.2.1.2 PIMECROLIMUS

11.4.1.2.1.2.1. MARKET VALUE (USD MN)

11.4.1.2.1.2.2. MARKET VOLUME (SU)

11.4.1.2.1.2.3. AVERAGE SELLING PRICE (USD)

11.4.1.2.1.3 OTHERS

11.4.1.2.2. BY DRUG TYPE

11.4.1.2.2.1 GENERICS

11.4.1.2.2.2 BRANDED

11.4.1.2.2.2.1. ASTAGRAF XL

70.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

71.2.1.1.1.1.1.1 MARKET VOLUME (SU)

72.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.2.2.2.2. ENVARSUSXR

73.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

74.2.1.1.1.1.1.1 MARKET VOLUME (SU)

75.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.2.2.2.3. PROGRAF

76.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

77.2.1.1.1.1.1.1 MARKET VOLUME (SU)

78.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.2.2.2.4. ELIDED

79.2.1.1.1.1.1.1 MARKET VALUE (USD MN)

80.2.1.1.1.1.1.1 MARKET VOLUME (SU)

81.2.1.1.1.1.1.1 AVERAGE SELLING PRICE (USD)

11.4.1.2.2.2.5. OTHERS

11.4.1.3. CALCIPOTRIENE (DOVONEX)

11.4.1.3.1. MARKET VALUE (USD MN)

11.4.1.3.2. MARKET VOLUME (SU)

11.4.1.3.3. AVERAGE SELLING PRICE (USD)

11.4.1.4. RUXOLITINIB (OPZELURA)

11.4.1.4.1. MARKET VALUE (USD MN)

11.4.1.4.2. MARKET VOLUME (SU)

11.4.1.4.3. AVERAGE SELLING PRICE (USD)

11.4.1.5. VITAMIN D

11.4.1.5.1. MARKET VALUE (USD MN)

11.4.1.5.2. MARKET VOLUME (SU)

11.4.1.5.3. AVERAGE SELLING PRICE (USD)

11.4.1.6. OTHERS

11.4.2 THERAPY

11.4.2.1. LIGHT THERAPY

11.4.2.2. REPIGMENTATION THERAPY

11.4.2.3. CAMOUFLAGE THERAPY

11.4.3 SURGERY

11.4.3.1. SKIN GRAFT

11.4.3.2. CELL TRANSPLANT

11.4.3.3. MICROPIGMENTATION

11.4.3.4. OTHERS

11.5 OTHERS VITILIGO

12 GLOBAL VITILIGO MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 TOPICAL

12.3 OTHERS

13 GLOBAL VITILIGO MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 DERMATOLOGY CLINICS

13.4 ACADEMIC AND RESEARCH INSTITUTES

13.5 OTHERS

14 GLOBAL VITILIGO MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 OTHERS

15 GLOBAL VITILIGO MARKET, BY GEOGRAPHY

15.1 GLOBAL VITILIGO MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.1.1. U.S. VITILIGO MARKET, BY TYPE

15.2.1.2. U.S. VITILIGO MARKET, BY ROUTE OF ADMINISTRATION

15.2.1.3. U.S. VITILIGO MARKET, BY END USER

15.2.1.4. U.S. VITILIGO MARKET, BY DISTRIBUTION CHANNEL

15.2.2 CANADA

15.2.3 MEXICO

15.2.4 DOMINICAN REPUBLIC

15.2.5 JAMAICA

15.2.6 PANAMA

15.3 EUROPE

15.3.1 GERMANY

15.3.2 FRANCE

15.3.3 U.K.

15.3.4 HUNGARY

15.3.5 LITHUANIA

15.3.6 AUSTRIA

15.3.7 IRELAND

15.3.8 NORWAY

15.3.9 POLAND

15.3.10 ITALY

15.3.11 SPAIN

15.3.12 RUSSIA

15.3.13 TURKEY

15.3.14 NETHERLANDS

15.3.15 SWITZERLAND

15.3.16 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 JAPAN

15.4.2 CHINA

15.4.3 TAIWAN

15.4.4 SOUTH KOREA

15.4.5 INDIA

15.4.6 AUSTRALIA

15.4.7 SINGAPORE

15.4.8 THAILAND

15.4.9 MALAYSIA

15.4.10 INDONESIA

15.4.11 PHILIPPINES

15.4.12 VIETNAM

15.4.13 REST OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ECUADOR

15.5.3 CHILE

15.5.4 COLOMBIA

15.5.5 VENEZUELA

15.5.6 ARGENTINA

15.5.7 PERU

15.5.8 CURAÇAO

15.5.9 PARAGUAY

15.5.10 URUGUAY

15.5.11 TRINIDAD AND TOBAGO

15.5.12 REST OF SOUTH AMERICA

15.6 MIDDLE EAST AND AFRICA

15.6.1 SOUTH AFRICA

15.6.2 SAUDI ARABIA

15.6.3 UAE

15.6.4 EGYPT

15.6.5 KUWAIT

15.6.6 ISRAEL

15.6.7 BOLIVIA

15.6.8 REST OF MIDDLE EAST AND AFRICA

15.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

16 GLOBAL VITILIGO MARKET, SWOT AND DBMR ANALYSIS

17 GLOBAL VITILIGO MARKET, COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 MERGERS & ACQUISITIONS

17.6 NEW PRODUCT DEVELOPMENT & APPROVALS

17.7 EXPANSIONS

17.8 REGULATORY CHANGES

17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

18 GLOBAL VITILIGO MARKET, COMPANY PROFILE

18.1 MAUFACTURING COMPANIES

18.1.1 INCYTE CORPORATION

18.1.1.1. COMPANY OVERVIEW

18.1.1.2. REVENUE ANALYSIS

18.1.1.3. GEOGRAPHIC PRESENCE

18.1.1.4. PRODUCT PORTFOLIO

18.1.1.5. RECENT DEVELOPMENTS

18.1.2 GLENMARK PHARMACEUTICALS

18.1.2.1. COMPANY OVERVIEW

18.1.2.2. REVENUE ANALYSIS

18.1.2.3. GEOGRAPHIC PRESENCE

18.1.2.4. PRODUCT PORTFOLIO

18.1.2.5. RECENT DEVELOPMENTS

18.1.3 GSK

18.1.3.1. COMPANY OVERVIEW

18.1.3.2. REVENUE ANALYSIS

18.1.3.3. GEOGRAPHIC PRESENCE

18.1.3.4. PRODUCT PORTFOLIO

18.1.3.5. RECENT DEVELOPMENTS

18.1.4 BAUSCH & LOMB

18.1.4.1. COMPANY OVERVIEW

18.1.4.2. REVENUE ANALYSIS

18.1.4.3. GEOGRAPHIC PRESENCE

18.1.4.4. PRODUCT PORTFOLIO

18.1.4.5. RECENT DEVELOPMENTS

18.1.5 DR REDDY LABORATORIES

18.1.5.1. COMPANY OVERVIEW

18.1.5.2. REVENUE ANALYSIS

18.1.5.3. GEOGRAPHIC PRESENCE

18.1.5.4. PRODUCT PORTFOLIO

18.1.5.5. RECENT DEVELOPMENTS

18.1.6 ACCORD HEALTHCARE

18.1.6.1. COMPANY OVERVIEW

18.1.6.2. REVENUE ANALYSIS

18.1.6.3. GEOGRAPHIC PRESENCE

18.1.6.4. PRODUCT PORTFOLIO

18.1.6.5. RECENT DEVELOPMENTS

18.1.7 PANACEA BIOTECH

18.1.7.1. COMPANY OVERVIEW

18.1.7.2. REVENUE ANALYSIS

18.1.7.3. GEOGRAPHIC PRESENCE

18.1.7.4. PRODUCT PORTFOLIO

18.1.7.5. RECENT DEVELOPMENTS

18.1.8 SANDOZ INTERNATIONAL GMBH

18.1.8.1. COMPANY OVERVIEW

18.1.8.2. REVENUE ANALYSIS

18.1.8.3. GEOGRAPHIC PRESENCE

18.1.8.4. PRODUCT PORTFOLIO

18.1.8.5. RECENT DEVELOPMENTS

18.1.9 VIATRIS (MYLAN)

18.1.9.1. COMPANY OVERVIEW

18.1.9.2. REVENUE ANALYSIS

18.1.9.3. GEOGRAPHIC PRESENCE

18.1.9.4. PRODUCT PORTFOLIO

18.1.9.5. RECENT DEVELOPMENTS

18.1.10 NOVARTIS

18.1.10.1. COMPANY OVERVIEW

18.1.10.2. REVENUE ANALYSIS

18.1.10.3. GEOGRAPHIC PRESENCE

18.1.10.4. PRODUCT PORTFOLIO

18.1.10.5. RECENT DEVELOPMENTS

18.1.11 GALDERMA

18.1.11.1. COMPANY OVERVIEW

18.1.11.2. REVENUE ANALYSIS

18.1.11.3. GEOGRAPHIC PRESENCE

18.1.11.4. PRODUCT PORTFOLIO

18.1.11.5. RECENT DEVELOPMENTS

18.1.12 TEVA PHARMACEUTICALS

18.1.12.1. COMPANY OVERVIEW

18.1.12.2. REVENUE ANALYSIS

18.1.12.3. GEOGRAPHIC PRESENCE

18.1.12.4. PRODUCT PORTFOLIO

18.1.12.5. RECENT DEVELOPMENTS

18.1.13 CIPLA, INC

18.1.13.1. COMPANY OVERVIEW

18.1.13.2. REVENUE ANALYSIS

18.1.13.3. GEOGRAPHIC PRESENCE

18.1.13.4. PRODUCT PORTFOLIO

18.1.13.5. RECENT DEVELOPMENTS

18.1.14 RALINGTON PHARMA

18.1.14.1. COMPANY OVERVIEW

18.1.14.2. REVENUE ANALYSIS

18.1.14.3. GEOGRAPHIC PRESENCE

18.1.14.4. PRODUCT PORTFOLIO

18.1.14.5. RECENT DEVELOPMENTS

18.1.15 JOHNSON & JOHNSON

18.1.15.1. COMPANY OVERVIEW

18.1.15.2. REVENUE ANALYSIS

18.1.15.3. GEOGRAPHIC PRESENCE

18.1.15.4. PRODUCT PORTFOLIO

18.1.15.5. RECENT DEVELOPMENTS

18.1.16 ELI LILLY

18.1.16.1. COMPANY OVERVIEW

18.1.16.2. REVENUE ANALYSIS

18.1.16.3. GEOGRAPHIC PRESENCE

18.1.16.4. PRODUCT PORTFOLIO

18.1.16.5. RECENT DEVELOPMENTS

18.1.17 SANOFI

18.1.17.1. COMPANY OVERVIEW

18.1.17.2. REVENUE ANALYSIS

18.1.17.3. GEOGRAPHIC PRESENCE

18.1.17.4. PRODUCT PORTFOLIO

18.1.17.5. RECENT DEVELOPMENTS

18.1.18 BOEHRINGER INGELHEIM

18.1.18.1. COMPANY OVERVIEW

18.1.18.2. REVENUE ANALYSIS

18.1.18.3. GEOGRAPHIC PRESENCE

18.1.18.4. PRODUCT PORTFOLIO

18.1.18.5. RECENT DEVELOPMENTS

18.1.19 ASTELLAS PHARMA

18.1.19.1. COMPANY OVERVIEW

18.1.19.2. REVENUE ANALYSIS

18.1.19.3. GEOGRAPHIC PRESENCE

18.1.19.4. PRODUCT PORTFOLIO

18.1.19.5. RECENT DEVELOPMENTS

18.1.20 BAXTER INTERNATIONAL INC

18.1.20.1. COMPANY OVERVIEW

18.1.20.2. REVENUE ANALYSIS

18.1.20.3. GEOGRAPHIC PRESENCE

18.1.20.4. PRODUCT PORTFOLIO

18.1.20.5. RECENT DEVELOPMENTS

18.1.21 PFIZER

18.1.21.1. COMPANY OVERVIEW

18.1.21.2. REVENUE ANALYSIS

18.1.21.3. GEOGRAPHIC PRESENCE

18.1.21.4. PRODUCT PORTFOLIO

18.1.21.5. RECENT DEVELOPMENTS

18.2 PIPELINE COMPANIES

18.2.1 AVITA MEDICAL

18.2.1.1. COMPANY OVERVIEW

18.2.1.2. REVENUE ANALYSIS

18.2.1.3. GEOGRAPHIC PRESENCE

18.2.1.4. PRODUCT PORTFOLIO

18.2.1.5. RECENT DEVELOPMENTS

18.2.2 ARCUTIS BIOTHERAPEUTICS

18.2.2.1. COMPANY OVERVIEW

18.2.2.2. REVENUE ANALYSIS

18.2.2.3. GEOGRAPHIC PRESENCE

18.2.2.4. PRODUCT PORTFOLIO

18.2.2.5. RECENT DEVELOPMENTS

18.2.3 CLINUVEL PHARMACEUTICALS

18.2.3.1. COMPANY OVERVIEW

18.2.3.2. REVENUE ANALYSIS

18.2.3.3. GEOGRAPHIC PRESENCE

18.2.3.4. PRODUCT PORTFOLIO

18.2.3.5. RECENT DEVELOPMENTS

18.2.4 EQUILLSUM BIO (BIONIZ THERAPEUTICS)

18.2.4.1. COMPANY OVERVIEW

18.2.4.2. REVENUE ANALYSIS

18.2.4.3. GEOGRAPHIC PRESENCE

18.2.4.4. PRODUCT PORTFOLIO

18.2.4.5. RECENT DEVELOPMENTS

18.2.5 BOSTON PHARMACEUTICALS

18.2.5.1. COMPANY OVERVIEW

18.2.5.2. REVENUE ANALYSIS

18.2.5.3. GEOGRAPHIC PRESENCE

18.2.5.4. PRODUCT PORTFOLIO

18.2.5.5. RECENT DEVELOPMENTS

18.2.6 ARCUTIS BIOTHERAPEUTICS

18.2.6.1. COMPANY OVERVIEW

18.2.6.2. REVENUE ANALYSIS

18.2.6.3. GEOGRAPHIC PRESENCE

18.2.6.4. PRODUCT PORTFOLIO

18.2.6.5. RECENT DEVELOPMENTS

18.2.7 ROVIANT SCIENCES

18.2.7.1. COMPANY OVERVIEW

18.2.7.2. REVENUE ANALYSIS

18.2.7.3. GEOGRAPHIC PRESENCE

18.2.7.4. PRODUCT PORTFOLIO

18.2.7.5. RECENT DEVELOPMENTS

18.2.8 DERMAVANT SCIENCES

18.2.8.1. COMPANY OVERVIEW

18.2.8.2. REVENUE ANALYSIS

18.2.8.3. GEOGRAPHIC PRESENCE

18.2.8.4. PRODUCT PORTFOLIO

18.2.8.5. RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

19 RELATED REPORTS

20 CONCLUSION

21 QUESTIONNAIRE

22 ABOUT DATA BRIDGE MARKET RESEARCH